198 related articles for article (PubMed ID: 32497121)
41. Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors.
Akahoshi K; Tanaka S; Mogushi K; Shimada S; Matsumura S; Akiyama Y; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M
J Gastroenterol; 2016 Sep; 51(9):910-22. PubMed ID: 26739296
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic and prognostic value of lncRNA cancer susceptibility candidate 9 in hepatocellular carcinoma.
Zeng YL; Guo ZY; Su HZ; Zhong FD; Jiang KQ; Yuan GD
World J Gastroenterol; 2019 Dec; 25(48):6902-6915. PubMed ID: 31908394
[TBL] [Abstract][Full Text] [Related]
43. Nuclear expression of phosphorylated TRAF2- and NCK-interacting kinase in hepatocellular carcinoma is associated with poor prognosis.
Jin J; Jung HY; Wang Y; Xie J; Yeom YI; Jang JJ; Lee KB
Pathol Res Pract; 2014 Oct; 210(10):621-7. PubMed ID: 25160513
[TBL] [Abstract][Full Text] [Related]
44. Proteomic analysis of HBV-associated HCC: insights on mechanisms of disease onset and biomarker discovery.
Niu D; Feng H; Chen WN
J Proteomics; 2010 May; 73(7):1283-90. PubMed ID: 20188222
[TBL] [Abstract][Full Text] [Related]
45. LncRNA GHET1 predicts poor prognosis in hepatocellular carcinoma and promotes cell proliferation by silencing KLF2.
Jin L; He Y; Tang S; Huang S
J Cell Physiol; 2018 Jun; 233(6):4726-4734. PubMed ID: 29139562
[TBL] [Abstract][Full Text] [Related]
46. A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma.
Hu F; Miao L; Zhao Y; Xiao YY; Xu Q
Drug Des Devel Ther; 2015; 9():3625-33. PubMed ID: 26203228
[TBL] [Abstract][Full Text] [Related]
47. Epigenomic profiling of DNA methylation for hepatocellular carcinoma diagnosis and prognosis prediction.
Zhang C; Ge S; Wang J; Jing X; Li H; Mei S; Zhang J; Liang K; Xu H; Zhang X; Zhang C
J Gastroenterol Hepatol; 2019 Oct; 34(10):1869-1877. PubMed ID: 31038805
[TBL] [Abstract][Full Text] [Related]
48. Downregulation of Nedd4L predicts poor prognosis, promotes tumor growth and inhibits MAPK/ERK signal pathway in hepatocellular carcinoma.
Zhao F; Gong X; Liu A; Lv X; Hu B; Zhang H
Biochem Biophys Res Commun; 2018 Jan; 495(1):1136-1143. PubMed ID: 29175326
[TBL] [Abstract][Full Text] [Related]
49. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
[TBL] [Abstract][Full Text] [Related]
50. Identification of AKT kinases as unfavorable prognostic factors for hepatocellular carcinoma by a combination of expression profile, interaction network analysis and clinical validation.
Zhang Y; Guo X; Yang M; Yu L; Li Z; Lin N
Mol Biosyst; 2014 Feb; 10(2):215-22. PubMed ID: 24247267
[TBL] [Abstract][Full Text] [Related]
51. Bioinformatics Analysis Reveals Distinct Molecular Characteristics of Hepatitis B-Related Hepatocellular Carcinomas from Very Early to Advanced Barcelona Clinic Liver Cancer Stages.
Kong FY; Wei X; Zhou K; Hu W; Kou YB; You HJ; Liu XM; Zheng KY; Tang RX
PLoS One; 2016; 11(7):e0158286. PubMed ID: 27454179
[TBL] [Abstract][Full Text] [Related]
52. Novel biomarkers in hepatocellular carcinoma.
De Stefano F; Chacon E; Turcios L; Marti F; Gedaly R
Dig Liver Dis; 2018 Nov; 50(11):1115-1123. PubMed ID: 30217732
[TBL] [Abstract][Full Text] [Related]
53. Metabolomic Biomarker Identification in Presence of Outliers and Missing Values.
Kumar N; Hoque MA; Shahjaman M; Islam SM; Mollah MN
Biomed Res Int; 2017; 2017():2437608. PubMed ID: 28293630
[TBL] [Abstract][Full Text] [Related]
54. Diagnostic significance and potential function of miR-338-5p in hepatocellular carcinoma: A bioinformatics study with microarray and RNA sequencing data.
Liang L; Gao L; Zou XP; Huang ML; Chen G; Li JJ; Cai XY
Mol Med Rep; 2018 Feb; 17(2):2297-2312. PubMed ID: 29207053
[TBL] [Abstract][Full Text] [Related]
55. Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
Fujikawa T; Shiraha H; Yamamoto K
Acta Med Okayama; 2009 Dec; 63(6):299-304. PubMed ID: 20035286
[TBL] [Abstract][Full Text] [Related]
56. Bioinformatics analysis of key biomarkers and potential molecular mechanisms in hepatocellular carcinoma induced by hepatitis B virus.
Li Z; Xu J; Cui H; Song J; Chen J; Wei J
Medicine (Baltimore); 2020 May; 99(20):e20302. PubMed ID: 32443377
[TBL] [Abstract][Full Text] [Related]
57. Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities.
De Matteis S; Ragusa A; Marisi G; De Domenico S; Casadei Gardini A; Bonafè M; Giudetti AM
Oxid Med Cell Longev; 2018; 2018():7512159. PubMed ID: 30524660
[TBL] [Abstract][Full Text] [Related]
58. Hypermethylation of NF-κB-Activating Protein-Like (NKAPL) Promoter in Hepatocellular Carcinoma Suppresses Its Expression and Predicts a Poor Prognosis.
Ng PKS; Lau CPY; Lam EKY; Li SSK; Lui VWY; Yeo W; Ng YK; Lai PBS; Tsui SKW
Dig Dis Sci; 2018 Mar; 63(3):676-686. PubMed ID: 29353445
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
[TBL] [Abstract][Full Text] [Related]
60. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
